Therapeutic Areas ace

Inquiry

* First Name
* Last Name
* Business Email
Phone
Company/Institution
Job Title
* Services or Products of Interest Drug Development Services for Diabetic Cardiovascular Complications
When do you expect your project to start?
Project Description
* All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
* Tick to confirm the Research Use Only (RUO) statement.

Drug Development Services for Diabetic Cardiovascular Complications

The complexity of the pathological mechanisms underlying cardiovascular complications of diabetes poses multiple challenges for preclinical research and development. Ace Therapeutics leverages deep expertise in diabetes research and integrated cross-disciplinary platforms to provide end-to-end therapeutic development services, from early target validation to preclinical candidate nomination, helping overcome drug development challenges.

Current Status of Therapeutic R&D for Diabetic Cardiovascular Complications

Effective glycemic control combined with early comprehensive vascular intervention is key to preventing and treating cardiovascular complications of diabetes. Beyond the widely recommended metformin, glucagon-like peptide-1 agonists, and sodium-glucose cotransporter-2 inhibitors, drugs such as aldose reductase inhibitors, peroxisome proliferator-activated receptor-gamma agonists, glucokinase agonists, and mitochondrial energy modulators are also under active development based on the latest molecular mechanisms. These interventions, together with emerging therapeutic agents, bring hope for the treatment of diabetic cardiovascular complications.

Current insights into proposed diabetes-CVD mechanisms Fig. 1 Examples of proposed mechanisms of diabetes and CVD. (Schmidt, A. M., 2019)

Our Drug Development Services for Diabetic Cardiovascular Complications

Our services are designed to accelerate the full development process of our clients' therapies for diabetic cardiovascular complications, from target discovery to preclinical validation.

Target Validation and Optimization

Validating the potential role of candidate targets in cardiovascular cell function using multi-omics data and gene editing technology.
Optimizing target intervention strategies through in vitro high-throughput screening and mechanism studies.

In Vitro Efficacy Screening and Evaluation

Utilizing iPSC-derived cardiomyocytes, endothelial cells, and vascular organoid models to simulate drug responses within disease microenvironments.
Key endpoints include cell viability, oxidative stress, fibrosis, and functional recovery.

In Vivo Pharmacodynamic Evaluation and Mechanism Research

Using STZ-induced and db/db models, combined with cardiac ultrasound, hemodynamic monitoring, and histopathological analysis, we comprehensively evaluate the efficacy of compounds.
Through molecular biomarker and signaling pathway analysis, we elucidate the mechanism of drug action.

Preclinical Safety Assessment Services

We evaluate the preclinical safety of drug candidates for our clients through comprehensive in vivo safety studies and PK/PD analysis.

Our Advanced Technology Platform

Human iPSC-derived cardiovascular cell platform: Provides humanized research models that simulate the in vivo microenvironment. These cells can be cultured under diabetic conditions (e.g., high glucose/palmitate) to model disease phenotypes for screening.
Multimodal imaging and functional analysis platform: Integrates high-resolution ultrasound, micro-CT, and electrophysiology technologies to enable dynamic quantification of cardiovascular structure and function.
High-throughput in vivo/in vitro screening platform: Combines high-content imaging with automated systems to achieve rapid screening of candidate molecules.

Ace Therapeutics leverages validated in vitro and in vivo models to accelerate breakthroughs in diabetic cardiovascular complications and streamline drug development. Contact us to explore customized preclinical development solutions tailored to your program.

Reference

Schmidt, A. M. Diabetes mellitus and cardiovascular disease: Emerging therapeutic approaches. Arteriosclerosis, thrombosis, and vascular biology. 39.4 (2019): 558-568.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services